Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany
Similar Posts
Update on Laryngeal Cancer
ByInnokeysSpeakers: 1. dr. Denny Satria Utama, Sp.T.H.T.L(K)., M.Si Med., FICS from Charitas Hospital Indonesia 2. Dr. dr. Fauziah Fardizza, Sp.T.H.T.K.L(K), FICS from…
New Marketing Authorization Approval in Myanmar for locally advanced unresectable or metastatic pancreatic cancer
ByInnokeysNew marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication…
Webinar – Current Treatment of Locally Advanced Head and Neck Cancer and The Result of Randomized Phase III Study of Nimotuzumab in Locally Advanced Head and Neck Cancer
ByInnokeysSpeakers: 1. Prof. Iyer Narayanan Gopalakrishna, Head and neck surgeon in National Cancer Centre and Singapore General Hospital 2. Prof. Dr. Kumar…
June 2017: Poster Presentation at ANZCHOG 2017
ByInnokeysAdelaide, South Australia (June 20, 2017) – Innokeys Pte Ltd attended ANZCHOG 2017 – a conference which is organized annually by the…
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
ByInnokeysMISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…
August 2013: Nimotuzumab in MOGA Australia
ByInnokeysMedical Oncology Group of Australia